Tagged Articles

pancreatic cancer 224 articles

Novo Nordisk becomes top diabetes drug seller with Victoza

Danish drug company Novo Nordisk has become the top seller of diabetes medications thanks to its blockbuster type 2 diabetes treatment Victoza (liraglutide), which brought in a whopping $2 billion in sales, up 15 percent over last year. Novo Nordisk displaced Sanofi, which sells numerous insulin products including Lantus, insulin-delivery devices as well as the diabetes drugs Lyxumia (lixisenatide) and Amaryl/Amarel (glimepiride). Victoza was approved by the Food and Drug Administration (FDA) in 2010 and became one of the newer members of a new class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta/Bydureon (exenatide) ... Read More

Sanofi ready to submit new type 2 diabetes drug for approval

After years of delay, drug maker Sanofi is almost ready to resubmit its type 2 diabetes treatment lixisenatide for Food and Drug Administration (FDA) approval, armed with a long-term study that the company hopes will squash any safety concerns posed by FDA panel advisors. Lixisenatide, which is already approved in Europe and marketed under the name Lyxumia, is a GLP-1 agonist that works similarly to already marketed drugs Byetta and Victoza. The drug was originally under review by an FDA advisory panel in 2013, but after Novo Nordisk’s GLP-1 drug was rejected due to safety concerns, Sanofi opted to pull lixisenatide’s ... Read More

Alarming number of pancreatitis, pancreatic cancer cases with diabetes drugs

Pancreatitis is a painful inflammation of the pancreas that can increase the likelihood of a patient developing pancreatic cancer, a health problem that type 2 diabetics are already at greater risk of developing. Interestingly, a study of drug adverse event reports reveals that common type 2 diabetes drugs have been associated with side effects that include acute pancreatitis and pancreatic cancer. Health informatics firm AdverseEvents scoured through post-marketing reports filed with the Food and Drug Administration (FDA) and found 1,900 cases of pancreatitis with AstraZeneca’s Byetta injection, 1,284 cases in patients taking Novo Nordisk’s Victoza, and 1,296 cases in patients ... Read More

Diabetes drugs may help reduce craving, but patients risk side effects

A class of type 2 diabetes drugs appear to change the brain’s response to food, leading to weight loss, and could also help people fight cravings for drugs, alcohol and nicotine as well, researchers suggest. The class of drugs, known as GLP-1 receptor agonists, or GLP-1 drugs, are known by the brand name diabetes treatments Bydureon, Byetta and Victoza. Since weight gain is already a contributing factor to the development of type 2 diabetes, the weight loss side effect offered by GLP-1 drugs is attractive. Late last year, Novo Nordisk received FDA approval for Saxenda, a high-dose version of its ... Read More

European regulators to review serious metabolic side effects with diabetes drugs

The European Medicines Agency (EMA) announced it will review the risk of a life threatening metabolic condition known as ketoacidosis from the use of certain type 2 diabetes drugs known as SGLT2 inhibitors. The review comes just after the U.S. Food and Drug Administration (FDA) ordered that warnings be placed on the labels of SGLT2 drugs advising patients and doctors of this risk. Ketoacidosis is a serious diabetes complication where the body produces excess blood acids, or ketones. It can lead to diabetic coma or death. It generally occurs when insulin levels are too low or during prolonged fasting. However, ... Read More

Certain diabetes drugs don’t protect against heart attacks, pancreatic cancer

A class of type 2 diabetes drugs do not increase heart risks in patients who take them, but doctors say they are disappointed the drugs don’t prevent heart attacks, the leading cause of death among diabetics. The class of diabetes treatment studied is known as GLP-1 drugs, and include the brand names Januvia and Byetta. They work by triggering insulin production after meals. The drugs are still fairly new to the market, having been introduced about a decade ago. But since the once-widely prescribed type 2 diabetes drug Avandia was severely restricted due to an increased risk of fatal heart attacks, drug ... Read More

Diabetes drug Victoza being tested as treatment for fatty liver disease

Drug maker Novo Nordisk continues to look for new uses for its type 2 diabetes drug Victoza despite serious side effects including pancreatic cancer. The drug company is currently testing Victoza as a treatment for fatty liver disease, a condition for which treatments are limited. Victoza, which contains the active ingredient liraglutide, was shown to resolve fatty liver disease in more than a third of patients who participated in a small phase II study conducted by researchers from University of Birmingham in Britain. Fatty liver disease is the accumulation of fat on the liver that causes inflammation and scarring. It ... Read More

Weight loss from newer diabetes drugs may come at steep price

Newer classes of type 2 diabetes drugs can help patients lose weight, but that benefit may come at a high price. Being overweight is a risk factor for type 2 diabetes. Patients diagnosed with the chronic disease are generally advised to adopt a healthy diet and get regular exercise to help keep their blood sugar levels in check. Uncontrolled diabetes can increase the risk of serious health problems including heart disease, kidney disease, some cancers, blindness, neuropathy, and dementia. Losing weight through diet and exercise can help diabetics better manage and, in some cases, fend off the disease. However, reaching ... Read More

New adverse reaction added to Januvia, Janumet safety label

The safety label of the type 2 diabetes drugs Januvia, Janumet and Janumet XR have been updated to include a warning for pruritus, also known as itching. Pruritus can be associated with a number of disorders, including dry skin, skin disease, pregnancy, and in some cases, cancer. It has also been associated with some medications. In some cases, pruritus is accompanied with a rash. Januvia, Janumet and Janumet XR contain the active ingredient sitagliptin. Janumet and Janumet also contain the diabetes medciation metformin. These drugs belong to a class of type 2 diabetes medications known as incretin mimetics. In 2013, ... Read More

FDA grants Fast Track status to advance pancreatic cancer drug

Merck and Threshold Pharmaceuticals’ experimental cancer drug evofosfamide has been granted Food and Drug Administration (FDA) Fast Track Designation for the treatment of advanced pancreatic cancer, a classification designed to accelerate the approval process for medications that treat serious or life-threatening diseases and fill an unmet medical need. Evofosfamide, previously known as TH-302, works by attacking body tissue that is short of oxygen supply, a characteristic of many cancer tumors because the cells often grow without connecting to the blood vessels around them. The medication is currently being tested in the third and last phase needed for FDA approval. Evofosfamide ... Read More